



## AMENDMENT TO THE CLAIMS

1. (Currently Amended) A compound ~~An imidazo[1,2-c]pyrimidinylacetic acid derivative~~ of the formula (I), its tautomeric or stereoisomeric form, ~~an ester, a hydrate, a solvate or a salt thereof:~~



wherein

Z<sup>1</sup> represents hydrogen, C<sub>1-6</sub> alkyl, benzyl, 4-methoxybenzyl or 3,4-dimethoxybenzyl;

 $R^1$  represents

in which


n represents an integer of 0 to 6;

Q<sub>1</sub> represents -NH-, -N(C<sub>1-6</sub> alkyl)-, or -O- ;

Y represents hydrogen, C<sub>3-8</sub> cycloalkyl optionally substituted by C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl fused by benzene, aryl or heteroaryl, wherein said aryl and heteroaryl are optionally substituted at a substitutable position with one or more substituents selected from the group consisting of cyano, halogen, nitro, guanidino, pyrrolyl, sulfamoyl, C<sub>1-6</sub> alkylaminosulfonyl, di(C<sub>1-6</sub> alkyl)aminosulfonyl, phenyloxy, phenyl, amino, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkoxy carbonyl, C<sub>1-6</sub> alkanoyl, C<sub>1-6</sub> alkanoylamino, carbamoyl, C<sub>1-6</sub> alkylcarbamoyl, di-(C<sub>1-6</sub> alkyl)carbamoyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri-halogen, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri-halogen and C<sub>1-6</sub> alkylthio optionally substituted by mono-, di-, or tri-halogen, or aryl fused by 1,3-dioxolane;


R<sup>2</sup> represents hydrogen or C<sub>1-6</sub> alkyl;

R<sup>3</sup> represents hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri-halogen, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri-halogen,



in which

R<sup>3a</sup> and R<sup>3b</sup> independently represent C<sub>3-8</sub> cycloalkyl, or C<sub>1-6</sub> alkyl optionally substituted by carboxy, C<sub>3-8</sub> cycloalkyl, carbamoyl, C<sub>1-6</sub> alkylcarbamoyl, aryl-substituted C<sub>1-6</sub> alkylcarbamoyl, C<sub>1-6</sub> alkylcarbamoyl, di(C<sub>1-6</sub> alkyl)carbamoyl, C<sub>3-8</sub> cycloalkylcarbamoyl, C<sub>3-8</sub> heterocyclocarbonyl, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino or C<sub>1-6</sub> alkoxy,



in which

q represents an integer of 1 to 3;

R<sup>3c</sup> represents hydrogen, hydroxy, carboxy, or C<sub>1-6</sub> alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted C<sub>1-6</sub> alkyl)carbamoyl;

Xa represents -O-, -S- or -N(R<sup>3d</sup>)-

in which


R<sup>3d</sup> represents hydrogen or C<sub>1-6</sub> alkyl; and

R<sup>4</sup> represents hydrogen or C<sub>1-6</sub> alkyl.

2. (Currently Amended) ~~The compound An imidazo[1,2-c]pyrimidinylacetic acid derivative~~ of the formula (I), its tautomeric or stereoisomeric form, ~~an ester, a hydrate, a solvate or a~~ salt thereof as claimed in claim 1,

wherein

R<sup>1</sup> represents



in which

n represents an integer of 0 to 2;


Q<sub>1</sub> represents -NH-, -N(C<sub>1-6</sub> alkyl)-, or -O- ;

Y represents C<sub>3-8</sub> cycloalkyl optionally substituted by C<sub>1-6</sub> alkyl, C<sub>3-8</sub> cycloalkyl fused by benzene, aryl selected from the group consisting of phenyl and naphthyl, or heteroaryl selected from the group consisting of indolyl, quinolyl, benzofuranyl, furanyl and pyridyl, wherein said aryl and heteroaryl are optionally substituted at a substitutable position with one or more substituents selected from the group consisting of cyano, halogen, nitro, pyrrolyl, sulfamoyl, C<sub>1-6</sub> alkylaminosulfonyl, di(C<sub>1-6</sub> alkyl)aminosulfonyl, phenyloxy, phenyl, C<sub>1-6</sub>alkylamino, di(C<sub>1-6</sub> alkyl)amino, C<sub>1-6</sub> alkoxy carbonyl, C<sub>1-6</sub> alkanoylamino, carbamoyl, C<sub>1-6</sub> alkylcarbamoyl, di-(C<sub>1-6</sub> alkyl)carbamoyl, C<sub>1-6</sub> alkylsulfonyl, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri-halogen, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri- halogen and C<sub>1-6</sub> alkylthio optionally substituted by mono-, di-, or tri- halogen; and

R<sup>2</sup> represents hydrogen.


3. (Currently Amended) (Currently Amended) The compound ~~An imidazo[1,2-  
e]pyrimidinylacetic acid derivative~~ of the formula (I), its tautomeric or stereoisomeric form, ~~an ester, a hydrate, a solvate~~ or a salt thereof as claimed in claim 1, wherein

R<sup>3</sup> represents hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri- halogen, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri- halogen,



in which

R<sup>3a</sup> and R<sup>3b</sup> independently represent C<sub>1-6</sub> alkyl optionally substituted by carboxy, C<sub>3-8</sub> cycloalkyl, carbamoyl, C<sub>1-6</sub> alkylcarbamoyl, di(C<sub>1-6</sub> alkyl)carbamoyl, C<sub>3-8</sub> cycloalkylcarbamoyl, C<sub>3-8</sub> heterocyclocarbonyl, C<sub>1-6</sub> alkylamino, di(C<sub>1-6</sub> alkyl)amino or C<sub>1-6</sub> alkoxy,



in which


$R^{3c}$  represents hydrogen, hydroxy, carboxy, or  $C_{1-6}$  alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted  $C_{1-6}$  alkyl)carbamoyl;

$Xa$  represents -O-, -S- or -N( $R^{3d}$ )-,

in which

$R^{3d}$  represents  $C_{1-6}$  alkyl.


4. (Currently Amended) (Currently Amended) ~~A compound~~ An imidazo[1,2-  
e]pyrimidinylacetic acid derivative of the formula (I-i), its tautomeric or stereoisomeric form, ~~an ester, a hydrate, a solvate or a salt thereof;~~



wherein

$Z^1$  represents hydrogen,  $C_{1-6}$  alkyl, benzyl, 4-methoxybenzyl or 3,4-dimethoxybenzyl;

$R^1$  represents



in which

n represents an integer of 0 to 2;


Q<sub>1</sub> represents -NH-, -N(C<sub>1-6</sub> alkyl)-, or -O- ;

Y represents phenyl, naphthyl, indolyl, quinolyl, benzofuranyl, furanyl or pyridyl,

wherein said phenyl, naphthyl, indolyl, quinolyl, benzofuranyl, furanyl and pyridyl are optionally substituted at a substitutable position with one or two substituents selected from the group consisting of cyano, halogen, nitro, phenyloxy, phenyl, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri-halogen, C<sub>1-6</sub> alkoxy optionally substituted by mono-, di-, or tri-halogen and C<sub>1-6</sub> alkylthio optionally substituted by mono-, di-, or tri-halogen;


R<sup>2</sup> represents hydrogen or C<sub>1-6</sub> alkyl;

R<sup>3</sup> represents hydrogen, halogen, C<sub>1-6</sub> alkyl optionally substituted by mono-, di-, or tri- halogen, C<sub>1-6</sub> alkoxy,



in which

$R^{3a}$  and  $R^{3b}$  independently represent  $C_{3-8}$  cycloalkyl, or  $C_{1-6}$  alkyl optionally substituted by  $C_{3-8}$  cycloalkyl, carbamoyl,  $C_{1-6}$  alkylcarbamoyl, (phenyl-substituted  $C_{1-6}$  alkyl)carbamoyl,  $C_{1-6}$  alkylcarbamoyl, di( $C_{1-6}$  alkyl)carbamoyl,  $C_{3-8}$  cycloalkylcarbamoyl,  $C_{3-8}$  heterocyclocarbonyl,  $C_{1-6}$  alkylamino, di( $C_{1-6}$  alkyl)amino or  $C_{1-6}$  alkoxy,



$R^{3c}$  represents hydrogen, hydroxy, carboxy, or  $C_{1-6}$  alkyl optionally substituted by hydroxy, carboxy or (phenyl-substituted  $C_{1-6}$  alkyl)carbamoyl; and

$R^4$  represents hydrogen or methyl.

5. (Currently Amended) ~~The compound~~ An imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I), its tautomeric or stereoisomeric form, ~~an ester, a hydrate, a solvate or a salt thereof as claimed in claim 1, wherein said compound~~ imidazo[1,2-c]pyrimidinylacetic acid derivative of the formula (I) is selected from the group consisting of:

[7-chloro-5-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid;

(7-chloro-5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetic acid;

{7-chloro-5-[4-(2-naphthoylamino)benzyl]imidazo[1,2-c]pyrimidin-8-yl}acetic acid;

[7-chloro-5-(4-{[(2E)-3-phenylprop-2-enoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid;

[7-chloro-5-(4-{[(2E)-3-(4-chlorophenyl)prop-2-enoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid;

(5-{4-[(3,4-dichlorobenzoyl)amino]benzyl}imidazo[1,2-c]pyrimidin-8-yl)acetic acid; and

[5-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)imidazo[1,2-c]pyrimidin-8-yl]acetic acid.

6. (Currently Amended) A pharmaceutical composition comprising a compound the imidazo[1,2-c]pyrimidinylacetic acid derivative, its tautomeric or stereoisomeric form, ~~an ester, a hydrate, a solvate~~ or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient, and one or more pharmaceutically acceptable excipients.
7. (Cancelled).
8. (Cancelled).
9. (Cancelled).
10. (Cancelled).
11. (Cancelled).
12. (Withdrawn-Currently Amended) A method for treating or preventing a disorder or disease associated with CRTH2 activity in a human[[s]] and or an animal[[s]] by administering to the human[[s]] and or animal[[s]] a CRTH2 antagonistically effective amount of a compound according to claim 1, its tautomeric or stereoisomeric form, or a salt thereof.
13. (Withdrawn-Currently Amended) A method for controlling a disorder or disease associated with CRTH2 activity in a human[[s]] and or an animal[[s]] by administering to the human[[s]] and or animal[[s]] a CRTH2 antagonistically effective amount of a compound according to claim 1, its tautomeric or stereoisomeric form, or a salt thereof.
14. (Currently Amended) The pharmaceutical composition as claimed in claim 6 [[7]], wherein the one or more pharmaceutically acceptable excipients is selected from carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating materials.



15. (Currently Amended) The pharmaceutical composition as claimed in claim 14, wherein the one or more pharmaceutically acceptable excipients is a carrier selected from lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate and methyl cellulose.
16. (Previously Presented) The pharmaceutical composition as claimed in claim 15, further comprising a tablet disintegrating agent selected from maize, starch, methyl cellulose, agar bentonite, xanthan gum and alginic acid.
17. (Previously Presented) The pharmaceutical composition as claimed in claim 15, wherein the carrier is in a form selected from tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
18. (Currently Amended) The pharmaceutical composition as claimed in claim 14, wherein the one or more pharmaceutically acceptable excipients is a binder selected from gelatin, natural sugars, beta-lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
19. (Currently Amended) The pharmaceutical composition as claimed in claim 14, wherein the one or more pharmaceutically acceptable excipients is a lubricant selected from magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate, sodium acetate, sodium chloride and talc.
20. (Previously Presented) The pharmaceutical composition as claimed in claim 6, wherein the amount of the active ingredient is from about 1 to about 99 weight percent, based on the total weight of the pharmaceutical composition.
21. (Withdrawn-Currently Amended) A unit dosage form comprising the compound ~~imidazo[1,2-c]pyrimidinylacetic acid derivative~~, its tautomeric or stereoisomeric form, ~~an~~

~~ester, a hydrate, a solvate~~ or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.

22. (Withdrawn) The unit dosage form of claim 21, wherein the quantity of the active ingredient is from about 0.1 to about 1000 milligrams.
23. (Withdrawn) The method of claim 12, wherein said disorder or disease is asthma, allergic rhinitis, atopic dermatitis or allergic conjuvatitis.
24. (Withdrawn) The method of claim 12, wherein said disorder or disease is Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria or basophilic leukocytosis.
25. (Cancelled).
26. (Cancelled).
27. (Cancelled).